ObsEva (OBSV) Competitors

Alterity Therapeutics (NASDAQ:ATHE) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.

Does the MarketBeat Community believe in ATHE or OBSV?

ObsEva received 314 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 62.50% of users gave Alterity Therapeutics an outperform vote while only 49.77% of users gave ObsEva an outperform vote.

Company	Underperform	Outperform
Alterity Therapeutics	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%
ObsEva	Outperform Votes 319 49.77%	Underperform Votes 322 50.23%

Which has more volatility & risk, ATHE or OBSV?

Alterity Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of ATHE or OBSV?

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable earnings & valuation, ATHE or OBSV?

Alterity Therapeutics has higher earnings, but lower revenue than ObsEva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$12.54M	N/A	N/A
ObsEva	$20.11M	0.00	-$58.38M	-$0.92	N/A

Do analysts prefer ATHE or OBSV?

Alterity Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 251.80%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alterity Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is ATHE or OBSV more profitable?

Alterity Therapeutics' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

Does the media favor ATHE or OBSV?

In the previous week, Alterity Therapeutics had 3 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for Alterity Therapeutics and 1 mentions for ObsEva. Alterity Therapeutics' average media sentiment score of 0.22 beat ObsEva's score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ObsEva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alterity Therapeutics beats ObsEva on 11 of the 14 factors compared between the two stocks.